Pharmaceutical CDMO Market Growth, Key Players, and Benefits

The global pharmaceutical CDMO market size was estimated at US$ 146.05 billion in 2023 and is projected to grow to US$ 315.08 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.24% from 2024 to 2034. The pharmaceutical CDMOs are growing due to the growing demand for pharmaceutical products.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5327

Pharmaceutical CDMO Market: Potential Aid for Pharma Companies

During the lengthy and intricate procedures required to research and manufacture novel therapeutic ingredients, pharmaceutical businesses encounter several hurdles. Bringing novel pharmaceutical products to market can be facilitated by partnering with the appropriate contract development and manufacturing organization (CDMO), which can save costs and offer scalability and expertise. Because pharmaceutical businesses need access to capacity or technological skills beyond what they have in-house and want to reduce risk by outsourcing to a secondary supplier, they contract drug manufacturers to CDMOs or CMOs.

Trends in the Pharmaceutical CDMO Market

Several notable developments have occurred recently in the pharmaceutical CDMO sector:

• October 2024: Strides Pharma Science secured Rs 801 crore in equity from domestic and international investors during its pre-listing phase.
• June 2023: Saudi Arabia’s Public Investment Fund (PIF) launched Lifera, a new commercial-scale CDMO aimed at boosting the country’s pharmaceutical manufacturing capabilities and positioning it as a major global hub.
• March 2023: Pharmaron invested £151 million in expanding its Gene Therapy CDMO facilities in the UK, increasing production space by over 8,000 square meters.

Opportunities in Personalized Medicine

The demand for personalized medicine is expected to drive significant growth in the CDMO market. Traditional manufacturing methods aren’t always suited to the customization required for personalized treatments. As a result, pharmaceutical companies are turning to CMOs with specialized capabilities to handle smaller, more complex production runs while maintaining high standards of efficacy, safety, and reliability.

Challenges: Intense Competition

The pharmaceutical CDMO market is becoming increasingly competitive, with numerous companies vying for the same customer base. This has led to price wars, as pharmaceutical companies search for cost-effective solutions. While competition drives innovation, it also challenges the market’s ability to grow sustainably, as the pressure to offer the best prices can hinder long-term profitability for CDMOs.

Regional Insights

• Asia Pacific: Dominated the pharmaceutical CDMO market in 2023, driven by growing production capacities in China, India, and Japan. China, in particular, holds the largest market share due to increasing collaborations between pharmaceutical firms and CDMOs.
• North America: Expected to experience the fastest growth during the forecast period. The U.S. and Canada are increasing investments in pharmaceutical R&D, and CDMOs are essential in navigating regulatory challenges while providing specialized knowledge and compliance expertise.
• United States: In 2023, the U.S. held the largest share of the pharmaceutical CDMO market. Pharmaceutical companies are increasingly outsourcing research and manufacturing to CDMOs to reduce costs, shorten time-to-market, and gain access to specialized knowledge.

Market Segments

• Product Segment: The Active Pharmaceutical Ingredient (API) sector led the market in 2023 and is projected to continue growing rapidly. Outsourcing API production allows pharmaceutical companies to focus on their core activities while benefiting from specialized expertise.
• Workflow Segment: The commercial production segment dominated the market, as CDMOs are critical for large-scale pharmaceutical manufacturing. The growth of generic and personalized medicine is fueling demand in this segment.
• Application Segment: Oncology was the leading application in the pharmaceutical CDMO market in 2023. CDMOs play a vital role in ensuring the safe, effective, and scalable production of cancer treatments, supporting everything from early-stage development to large-scale manufacturing.
• End-Use Segment: Large pharmaceutical companies hold the largest share of the market, with a growing demand for CDMO services to manage research, development, and manufacturing needs. The trend towards outsourcing is expected to continue as companies seek to improve efficiency and reduce costs.

Top Companies in the Pharmaceutical CDMO Market

• Veranova
• Sterling
• Fareva
• Pfizer Centre One
• AjiBio
• Uquifa
• Farmhispania
• Carbogen Amcis
• Evonik
• FIS (Fabbrica Italiana Sintetici S.p.A.)
• Almac
• Dottikon
• Curia
• CordenPharma International
• Piramal Pharma Solutions
• Samsung Biologics
• WuXi AppTec, Inc.
• Siegfried Holding AG
• Cambrex Corporation
• Bushu Pharmaceuticals Ltd.
• EuroAPI
• LabCorp
• Sequens
• Hovione
• Nipro Corporation
• Catalent, Inc.
• Thermo Fisher Scientific, Inc.
• Recipharm AB
• Axplora
• Lonza

Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/pharmaceutical-cdmo-market-sizing

To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5327

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Visit Dental Specifics: https://www.towardsdental.com

Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare